BREAKING NEWS: VALSARTAN MDL CREATED & SENT TO JUDGE KUGLER IN THE DISTRICT OF NEW JERSEY

On February 14, 2019, both class action and personal injury cases involving contaminated valsartan-containing drugs were consolidated into a multi-district litigation (MDL) in the District of New Jersey before the Honorable Robert B. Kugler.

Valsartan is a medication prescribed to treat high blood pressure and related conditions.  Recent investigations by the FDA revealed that pills distributed by at least four Active Pharmaceutical Ingredient (API) manufacturers were contaminated with carcinogenic substances, called NDMA and NDEA.  As a result, both the US FDA and the European Medicines Agency (among other foreign regulatory agencies) predicted that some consumers who took these contaminated pills for a number of years will get cancer.

This MDL will be comprised of both personal injury cases, as well as class actions. As of the time the Judicial Panel on Multidistrict Litigation (JPML) issued its order creating the MDL, there were approximately 40 cases filed.  The MDL includes all manufacturers of the recalled valsartan. For a list of these manufacturers, visit the FDA’s website.

The JPML determined that New Jersey was an appropriate venue for the litigation, primarily because many defendants have headquarters in New Jersey, and it is likely that both relevant documents and witnesses will be located in New Jersey as well.  Further, Judge Kugler previously presided over a litigation involving a different ARB drug, olmesartan (Benicar).

There is currently no decision on whether other angiotensin II receptor blockers (ARBs), such as irbesartan and losartan, will be included in this MDL.

GoldenbergLaw is currently accepting valsartan, losartan, and irbesartan cases.  To learn more about this litigation, please visit our valsartan page. You can also find out whether your medication has been recalled by visiting the FDA’s website.  If you or a loved one took one of these drugs and contracted liver, colorectal, stomach, intestinal, kidney, and pancreatic cancer, please contact us. We deliver the gold standard advocacy you deserve.

Valsartan Recall Expands: Mylan Recalls Over 100 Lots

Pharmaceutical company Mylan is recalling some of its blood pressure medications due to cancer concerns. The medications recalled all contain Valsartan. Since July 2018, the FDA has been recalling Valsartan due to finding trace amounts of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), which are classified as probable human carcinogens by the Environmental Protection Agency.

Mylan has recalled a total of 119 lots of medication containing Valsartan, including Amlodipine and Valsartan Tablets, Valsartan Tablets, and Hydrochlorothiazide Tablets. The list of all recalled lots can be found here.

This is the largest recall in FDA history. Mylan joins a growing number of companies that have recalled lots that contain Valsartan, Irbesartan, and Losartan due to carcinogen contamination. GoldenbergLaw is committed to holding these pharmaceutical companies accountable. If you or a loved one has taken Valsartan, Irbesartan, or Losartan and have been diagnosed with cancer, contact GoldenbergLaw.

Will There Be a Sartan Drug Recall?

After learning about the Valsartan recall due to contamination, many patients were switched from Valsartan to other sartan drugs. But now many are questioning the safety of these sartan drugs after learning that the European Medicines Agency (EMA) is investigating candesartan, irbesartan, losartan, and olmesartan for the same reason. It’s only a matter of time before the EMA and FDA determine if there should be a sartan drug recall.

The EMA announced that low levels of N-nitrosodiethylamine (NDEA) were detected in losartan, prompting the precautionary investigation into other sartan drugs because of the similar chemical structure. “National authorities in the EU are currently considering whether to recall medicines containing Aurobindo Pharma’s irbesartan from pharmacies as a precaution,” the EMA said.

The EMA will be increasing supervision on Chinese company Zheijiang Huahai to review the manufacturing process of other active substances. The investigation will help the European Commission to determine if there should be a sartan drug recall.

If the European Union decides to issue a sartan drug recall, the FDA may follow suit. GoldenbergLaw will continue to update on the Valsartan and sartan investigation.

If you or a loved one took Valsartan and was diagnosed with liver, colorectal, stomach, pancreatic, kidney or bladder cancer, please contact us. We have successfully resolved similar cases, including many involving the high blood pressure medication Benicar. Call GoldenbergLaw, and leave the sleepless nights to us.

Talk With Us >